Clinical trials: Pituitary Cancer
Pituitary Tumor, ACTH-producing Pituitary Tumour
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph…
- Trial name
- PASSILCORT (NCT02749227)
- Testing
- Pasireotide LAR
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Hypogonadotropic Hypogonadism, Kallmann Syndrome
Kisspeptin Administration in the Adult
The goal of this study is to learn about the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that causes the release of other hormones, including gonadotropin-releasing hormone…
- Conditions
- Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS
- Trial name
- NCT00914823
- Testing
- kisspeptin 112-121, GnRH
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Pituitary Adenoma Invasive, Nasal Obstruction
Nasal Obstruction Compared by Rhinomanometry and Nasal Inspiratory Peak Flow After Endoscopic Nasal Surgery
The aim of the project is to determine whether nasal inspiratory peak flow is sufficient for preoperative and postoperative measurement of nasal patency compared to rhinomanometry.
- Trial name
- NCT05921396
- Testing
- Nasal patency - rhinomanometry, Nasal patency - nasal inspiratory peak flow
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- University Hospital Ostrava
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Pituitary Tumor
Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
Investigators hypothesized that propofol dose for pituitary somatotroph patients might differ from nonfunctioning pituitary tumor, and investigators will evaluate a target controlled infusion (TCI) effect site concentration (Ce)…
- Trial name
- NCT03465423
- Testing
- Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Yonsei University
Pituitary Tumor
Nasal Packing Following Endoscopic Endonasal Pituitary Resection
There is considerable controversy about the use of nasal packing following endoscopic endonasal resection of pituitary tumors as a necessary treatment amongst Rhinology-Skull Base Surgeons.
- Trial name
- NCT03677713
- Testing
- No nasal packing., Nasal Packing
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ottawa Hospital Research Institute
Growth Hormone Deficiency, Pituitary Tumor
Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas
The purpose of this study is to determine if patients with a history of nonsecreting pituitary adenomas with untreated GH deficient patients have profiles consistent with increased cardiovascular risk compared to patients without…
- Trial name
- NCT00646308
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Columbia University
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Pituitary Neoplasms
Radiomic and Pathomic Study of Pituitary Adenoma Using Machine Learning
Refractory pituitary adenoma is characterized by invasive tumor growth, continuous growth and/or hormone hypersecretion in spite of standardized multi-modal treatment such as surgeries, medications or radiations.
- Trial name
- NCT05108064
- Testing
- Artificial intelligence model
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
Pituitary Tumor
Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
The purpose of the study is to determine genetic links among blood-relatives and between spouses of patients with pituitary tumors.
- Trial name
- NCT00598949
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Cedars-Sinai Medical Center
Intraoperative Pain Control
Infraorbital Nerve Block for Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor
Perioperative pain relief during endoscopic transsphenoidal pituitary surgery is generally treated with opioids either morphine sulfate or fentanyl.
- Trial name
- NCT04785222
- Testing
- dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine
- Volunteers
- 63 people
- Sponsor
- Chiang Mai University
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Pituitary Adenoma, Surgery-Complications
Prognostic Indicators in Pituitary Adenoma Surgery: a Comprehensive Analysis of Surgical Outcomes and Complications.
Predicting the outcome of pituitary surgery, particularly the risk of complications, is a critical determinant in selecting the appropriate treatment modality for patients.
- Trial name
- Hyp'Op (NCT06053437)
- Where
- France
- Volunteers
- 211 people
- Sponsor
- Central Hospital, Nancy, France
Cushing's Disease
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly…
- Trial name
- NCT00612066
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Acromegaly, Nonfunctioning Pituitary Adenoma
Direct Versus Video Laryngoscopy in Patients With Acromegaly
Acromegaly is associated with craniofacial skeletal changes and upper airway soft tissue hypertrophy, which may increase the risk of difficult laryngoscopy and tracheal intubation.
- Trial name
- ACRO-VL (NCT07659912)
- Volunteers
- 40 people
- Sponsor
- Muzaffer GENCER
Prolactinoma, Prolactin-Producing Pituitary Tumor
Validation of a Quality of Life Metric "Prolac-10"
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
- Conditions
- Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma
- Trial name
- Prolac-10 (NCT04106531)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University
Acromegaly Due to Pituitary Adenoma
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma
- Trial name
- GA-9 (NCT03807076)
- Testing
- GIP-A
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- University of Copenhagen
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Endocrine Disorders, Adiposity
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary…
- Conditions
- Endocrine Disorders, Adiposity, Pituitary Adenoma, Cushing Syndrome
- Trial name
- NCT06326853
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele